登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式(希尔记法):
C13H16N2O2
化学文摘社编号:
分子量:
232.28
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51111800
EC Number:
204-756-4
MDL number:
biological source
synthetic
Quality Level
assay
≥98% (TLC)
form
powder or crystals
color
white
mp
152-154 °C (lit.)
solubility
H2O: slightly soluble 0.2 mg/mL, 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 1.2 mg/mL, 0.1 M HCl: soluble, acetonitrile: soluble, methanol: soluble
originator
Novartis
storage temp.
room temp
SMILES string
CCC1(CCC(=O)NC1=O)c2ccc(N)cc2
InChI
1S/C13H16N2O2/c1-2-13(8-7-11(16)15-12(13)17)9-3-5-10(14)6-4-9/h3-6H,2,7-8,14H2,1H3,(H,15,16,17)
InChI key
ROBVIMPUHSLWNV-UHFFFAOYSA-N
Gene Information
human ... CYP11A1(1583), CYP17A1(1586), CYP19A1(1588)
rat ... Cyp19a1(25147)
Application
DL-Aminoglutethimide has been used:
- as a steroid synthesis inhibitor to study its effects on steroid synthesis in amphibian Xenopus laevis oocytes
- as an adrenostatic compound to study its effects on full form Enhanced green fluorescent protein (EGFP) andproopiomelanocortin (POMC) expression in the anterior domain of zebrafish pituitary corticotrophs
- as an inhibitor of steroidogenic enzymes to study its effects on estrogen receptor (ER) mRNA levels in mouse tumor leydig cell line
Biochem/physiol Actions
DL-Aminoglutethimide is a derivative of the sedative glutethimide. Originally introduced as an anticonvulsant, it was found to cause adrenal insufficiency. Blocks adrenal steroidogenesis by inhibiting the enzymatic conversion of cholesterol to pregnenolone. It also blocks the peripheral conversion (aromatization) of androgenic precursors to estrogens. The D-isomer is 30 times more potent at inhibiting aromatase activity, whereas the L-isomer is more potent at inhibiting cholesterol side-chain cleavage (steroidogenesis).
Derivative of the sedative glutethimide. Originally introduced as an anticonvulsant, it was found to cause adrenal insufficiency. Blocks adrenal steroidogenesis by inhibiting the enzymatic conversion of cholesterol to pregnenolone.
Features and Benefits
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Packaging
Bottomless glass bottle. Contents are inside inserted fused cone.
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
法规信息
监管及禁止进口产品
此项目有
Biphasic regulation of the messenger ribonucleic acid coding for the estrogen receptor by cyclic adenosine 3?: 5?-monophosphate in tumor Leydig cells
Ree A H, et al.
Cancer research, 50(5), 1528-1531 (1990)
Arup Maiti et al.
Journal of medicinal chemistry, 50(12), 2799-2806 (2007-05-22)
An efficient and economical synthesis of the naturally occurring aromatase inhibitor abyssinone II was performed. The synthesis features an optimized aromatic prenylation reaction in which an arylcopper intermediate is reacted with prenyl bromide to afford a key intermediate that was
P E Lønning et al.
Drugs, 35(6), 685-710 (1988-06-01)
During the last decade aminoglutethimide has been recognised as a valuable alternative in endocrine therapy for advanced breast cancer. Although some side effects do occur, most often these are initial effects which subside within a few weeks, and cessation of
Activation of the progesterone-signaling pathway by methyl-beta-cyclodextrin or steroid in Xenopus laevis oocytes involves release of 45-kDa Galphas
Sadler S E, et al.
Developmental Biology, 322(1), 199-207 (2008)
Aminoglutethimide in the treatment of advanced breast cancer.
R C Stuart-Harris et al.
Cancer treatment reviews, 11(3), 189-204 (1984-09-01)
相关内容
Product Information Sheet
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| A9657-1G | 04061826740989 |
| A9657-100MG | 04061833412183 |
| A9657-500MG | 04061833030585 |
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持